Actively Recruiting
Evaluating NVG-291 for Improving Function and Safety in Adults with Chronic Cervical Spinal Cord Injury A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
Led by NervGen Pharma · Updated on 2026-11-04
150
Participants Needed
23
Research Sites
23 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the investigational peptide NVG-291 in adults who have chronic cervical motor-incomplete spinal cord injury. This Phase 3 study aims to learn if NVG-291 can improve hand function and daily activities, and to monitor the safety of the treatment. NVG-291 is designed to promote nervous system repair by targeting pathways that may block nerve regeneration after spinal cord injury. There are no currently approved drugs specifically intended to promote neurological repair in this population. In this randomized, double-blind, placebo-controlled study, approximately 150 participants will be assigned to receive either NVG-291 or a placebo by daily subcutaneous injection for 12 weeks. After the treatment period, participants will be followed for an additional 4 weeks without intervention to assess if any functional improvements persist. An optional open-label extension may allow participants initially on placebo to receive NVG-291. Participants will attend clinic visits for safety checks and assessments of hand function, walking ability, daily activities, and quality of life. Researchers will collect data using tests, questionnaires, and interviews about changes in condition. Safety will be monitored through adverse event recording and laboratory tests. The main outcome is the change in hand function measured by the GRASSP Quantitative Prehension score from baseline to Week 12.
CONDITIONS
Brief Title
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
Research Team
N
NervGen Study Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here